You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.
AbcamBiochemicals (Asc-317)

NNC 05-2090 (ab120317)

Submit a Question

Overview

  • Product nameNNC 05-2090
  • Description
    GABA uptake inhibitor
  • Biological descriptionGABA uptake inhibitor, selective for the BGT-1 transporter (Ki values are 1.4, 19, 41 and 15 μM at BGT-1, GAT-1, GAT-2 and GAT-3 respectively). Also active at α1- and D2-receptors (IC50 values are 266 and 1632 nM respectively). Anti-convulsant in vivo.
  • Purity> 99%

    • Properties

  • Chemical name1-[3-(9H-Carbazol-9-yl)propyl]-4-(2-methoxyphenyl)-4-piperidinol hydrochloride
  • Molecular Weight451.01
  • Chemical structureChemical Structure
  • Molecular formulaC27H30N2O2.HCl
  • CAS Number184845-43-0
  • PubChem identifier18782760
  • Storage instructionsStore at room temperature (desiccating conditions).
  • Solubility overviewSoluble in DMSO to 100 mM
  • Handling

    Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 6 months.

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

  • SMILESCl.COc1ccccc1C5(O)CCN(CCCn4c2ccccc2c3ccccc34)CC5
  • Source

    Synthetic

  • Research Areas

    • References for NNC 05-2090 (ab120317)

    This product has been referenced in:
    • Thomsen C  et al. 1-(3-(9H-carbazol-9-yl)-1-propyl)-4-(2-methoxyphenyl)-4-piperidinol, a novel subtype selective inhibitor of the mouse type II GABA-transporter. Br J Pharmacol 120:983-5 (1997). Read more (PubMed: 9134205) »
    • Dalby NO  et al. Anticonvulsant properties of two GABA uptake inhibitors NNC 05-2045 and NNC 05-2090, not acting preferentially on GAT-1. Epilepsy Res 28:51-61 (1997). Read more (PubMed: 9255599) »

    See 0 Publications for this product

    Publishing research using ab120317 ? Please let us know so that we can cite the reference in this datasheet

    Product Wall

    Submit a Question for ab120317

    There are currently no Questions for ab120317.
    Please use the link above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE, NOT FOR USE IN HUMANS"